Leksell Gamma Knife Market Size, Trends & Growth Opportunity By Product Type, By Treatment Indication, By End User, By Regulatory Environment, By Region and Forecast Till 2030

Report ID : AMR1006083 | Industries : Healthcare | Published On :September 2026 | Page Count : 245

Request Sample
Ask for Customization

The Leksell Gamma Knife market covers Leksell Gamma Knife stereotactic radiosurgery systems and directly related software, service, maintenance, upgrade and modernisation offerings supplied globally.

A Leksell Gamma Knife system is a capital equipment platform used in stereotactic radiosurgery, and this report describes the category strictly as a market segment.

It makes no claim about treatment efficacy, clinical outcome, safety outcome or comparative clinical superiority for any platform, indication or company described on these pages.

Eight segmentation dimensions appear in this report, and the first two describe the platform type supplied and the patient volume category of the centre operating it.

Product type spans five categories, from the Leksell Gamma Knife Icon and earlier installed Gamma Knife platforms through software and treatment planning solutions to service and maintenance programmes and upgrades and modernisation services.

Patient volume category covers three categories: high-volume radiosurgery centres, mid-volume specialty centres and emerging radiosurgery programmes.

The most useful commercial observation about this market is that patient volume category, not platform type alone, is the first investment decision a centre actually makes.

Whether a centre operates at high, mid or emerging patient volume shapes whether it can justify a newer Icon platform and associated software investment, or instead operates an earlier installed platform through a service and upgrade path.

Treatment indication spans nine categories including brain metastases, acoustic neuroma, meningioma, arteriovenous malformations, trigeminal neuralgia, pituitary adenoma, gliomas, functional neurosurgery applications and other intracranial disorders, and clinical workflow covers three categories spanning standalone radiosurgery programmes, integrated oncology centres and multidisciplinary brain tumour centres.

End user is the widest dimension in this report at six categories, spanning academic medical centres, cancer hospitals, neurosurgical hospitals, multi-specialty hospitals, government healthcare institutions and private healthcare groups, and ownership model spans four categories including public hospitals, private hospital networks, university hospitals and research institutions.

Procurement model covers five categories including direct purchase, tender-based procurement, public healthcare procurement, leasing and financing models and strategic partnership models, and regulatory environment completes the segmentation across three categories: FDA-regulated markets, CE-Mark markets and emerging regulatory jurisdictions.

This report covers Leksell Gamma Knife systems and directly related offerings across North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

It excludes broader linear accelerator-based radiotherapy systems and general neurosurgical instrumentation outside this report's Gamma Knife-specific scope, except where named as competitive alternatives in the competitive landscape.

Buyer intelligence in the full report maps academic healthcare systems, cancer care networks, neuroscience institutes, government hospital groups and private hospital chains across the report's five covered regions, including a dedicated strategic relevance assessment for Elekta.

Competitive benchmarking compares manufacturers across estimated market position, installed base, procedure volumes, pricing positioning and five further metrics without disclosing proprietary competitive positioning data.

Elekta manufactures the Leksell Gamma Knife platform that gives this market its name, and the report's competitive landscape also compares it against manufacturers of directly comparable stereotactic radiosurgery and radiotherapy technologies.

Market Size and Growth Forecast (2026 to 2030)

The Leksell Gamma Knife market is estimated at approximately USD 475 Million in 2025 and is projected to reach approximately USD 620 Million by 2030, expanding at a compound annual growth rate of roughly 5.5 percent.

The estimate covers Leksell Gamma Knife systems and directly related software, service, maintenance, upgrade and modernisation offerings, and excludes broader linear accelerator-based radiotherapy systems and general neurosurgical instrumentation.

The Leksell Gamma Knife Icon together with software and treatment planning solutions account for the largest product type category by revenue, while upgrades and modernisation services form a fast-growing product type category tied to the ageing earlier installed platform base.

High-volume radiosurgery centres account for the largest patient volume category by revenue, and emerging radiosurgery programmes form the fastest-growing patient volume category as new markets establish initial installed base.

Brain metastases and meningioma together account for the largest treatment indication category by procedure volume, while functional neurosurgery applications form a fast-growing treatment indication category tied to broader multidisciplinary brain tumour centre adoption.

Academic medical centres and cancer hospitals together account for the largest end-user category, and private healthcare groups form a fast-growing end-user category tied to private hospital network expansion in several emerging markets.

Public hospitals and university hospitals together account for the largest ownership model category, reflecting the concentration of installed base within public and academic healthcare systems.

Tender-based procurement and public healthcare procurement together account for the largest procurement model category, and strategic partnership models form a fast-growing procurement category tied to university hospital and research institution acquisition.

FDA-regulated markets and CE-Mark markets together account for the largest regulatory environment category, reflecting their established position across the majority of installed base tracked in this report.

North America and Europe together account for the largest regional concentration in this report, and Asia-Pacific forms the fastest-growing region tied to oncology programme expansion and government tender activity.

The forecast assumes government tender and public healthcare procurement budgets continue broadly on recent trends, and a sustained slowdown in capital equipment budgets would move the trajectory.

MetricValue
Market Size (2025)Approximately USD 475 Million
Forecast Size (2030)Approximately USD 620 Million
CAGR (2025-2030)Approximately 5.5%
Base Year2025
Forecast Period2026-2030 (5-year)
Scope NoteLeksell Gamma Knife systems and directly related software, service, maintenance, upgrade and modernisation offerings only; excludes broader linear accelerator-based radiotherapy systems and general neurosurgical instrumentation
Largest Product CategoryLeksell Gamma Knife Icon and software and treatment planning solutions
Fastest-Growing Product CategoryUpgrades and modernisation services
Largest End-User CategoryAcademic medical centres and cancer hospitals
Fastest-Growing End-User CategoryPrivate healthcare groups
Largest Regulatory CategoryFDA-regulated markets and CE-Mark markets
Largest Regional ConcentrationNorth America and Europe

Market Drivers

Oncology programme expansion and neurosurgery capacity growth across hospital systems investing in stereotactic radiosurgery capability.

Technology modernisation and replacement demand among institutions operating earlier installed Gamma Knife platforms.

Clinical differentiation objectives among academic medical centres and cancer hospitals building out neuro-oncology service lines.

Rising government tender and public healthcare procurement activity supporting capital equipment acquisition across public and private healthcare systems.

Growth in software and treatment planning investment extending the functional life and capability of the existing installed base.

Expansion of multidisciplinary brain tumour centres, which broaden the referral base feeding radiosurgery programmes beyond standalone specialty centres alone.

Rising reimbursement support for outpatient and single-session radiosurgery procedures in several established healthcare systems.

Growth in private hospital network investment in neuroscience and oncology service lines across emerging markets.

Increasing academic and clinical collaboration activity supporting broader adoption across research institutions and university hospitals.

Market Restraints

High capital cost and long public-sector and academic-institution procurement cycles associated with a single-purpose stereotactic radiosurgery system.

Dependence on government tender and public healthcare procurement budgets, which are outside any manufacturer's control.

Competition from alternative radiosurgery and radiotherapy technologies for the same capital equipment budget.

Long specification, credentialing and regulatory approval periods before a new manufacturer or platform gains meaningful installed base share.

Fragmented demand across smaller or emerging radiosurgery programmes, which raises the cost of serving that segment commercially relative to established high-volume centres.

Skilled neurosurgery and radiation oncology personnel availability constraints, which can affect both new programme establishment and ongoing procedure throughput.

Extended service and technical support expectations from academic and government buyers, which add ongoing commercial obligations beyond the initial system acquisition.

Local regulatory variation across jurisdictions, which requires manufacturers to maintain separate approval and certification documentation across overlapping regimes.

PROCUREMENT INSIGHT

Academic medical centres and government hospital groups increasingly evaluate a manufacturer's service and software roadmap well before a specific tender is issued, meaning a long specification and credentialing period functions as a genuine barrier to entry rather than a one-time onboarding cost.

 

Market Opportunities

Considerable untapped opportunity identified in the report competitive mapping.

Emerging market penetration opportunities across Latin America, Asia-Pacific and Middle East and Africa markets where installed base remains comparatively limited.

Service revenue growth opportunities tied to upgrades and modernisation of the existing installed base.

Growth in software and treatment planning capability, which several manufacturers are using to differentiate their platforms.

Underserved demand among emerging radiosurgery programmes, where fewer manufacturers have established deep specification and training support.

Expansion of strategic partnership procurement models, which several university hospitals and research institutions are using to access newer platforms without a direct capital purchase.

Growth in multidisciplinary brain tumour centre formation, broadening the addressable referral base for existing and new radiosurgery programmes alike.

Multi-region regulatory alignment activity, which reduces the number of separate approval pathways a manufacturer must maintain across FDA-regulated, CE-Mark and emerging jurisdictions.

MARKET SHIFT

Emerging radiosurgery programmes across Latin America, Asia-Pacific and Middle East and Africa markets are underserved by manufacturers with deep specification and training support even as these regions form this market's fastest-growing patient volume and regional categories, leaving a support gap that strategic partnership procurement models are only beginning to close.

 

Gamma Knife Platform Types and Patient Volume Categories

Buyers evaluating gamma knife platform types increasingly weigh service and software roadmap alongside platform generation when scoping an investment, since the Leksell Gamma Knife Icon, earlier installed platforms, software and treatment planning solutions, service and maintenance programmes, and upgrades and modernisation services are supplied differently across high-volume, mid-volume and emerging radiosurgery centres.

Treatment Indications and Clinical Workflow Models

Brain metastases, acoustic neuroma, meningioma, arteriovenous malformations, trigeminal neuralgia, pituitary adenoma, gliomas, functional neurosurgery applications and other intracranial disorders are addressed across standalone radiosurgery programmes, integrated oncology centres and multidisciplinary brain tumour centres, and this spread of gamma knife treatment indications shapes which referral pathway a given case ultimately follows.

End Users, Ownership Models and Procurement Pathways

Academic medical centres, cancer hospitals, neurosurgical hospitals, multi-specialty hospitals, government healthcare institutions and private healthcare groups acquire systems through public hospital, private hospital network, university hospital and research institution ownership structures under direct purchase, tender-based, leasing and strategic partnership procurement models, a mix of gamma knife end users that varies considerably by region.

Regulatory and Market Access Environment

FDA-regulated markets, CE-Mark markets and emerging regulatory jurisdictions each impose a different sequencing on market entry, and this gamma knife regulatory environment increasingly determines which manufacturers can compete in a given country before procurement even begins.

Leksell Gamma Knife Market, By Region

This report covers North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa, reflecting where global Leksell Gamma Knife installed base and demand is concentrated.

North America accounts for the largest regional concentration in this report, covered through the United States and Canada, with demand concentrated among academic medical centres, cancer hospitals and government healthcare institutions.

Europe represents a steady, established regional concentration, covered through Germany, the United Kingdom, France, Italy, Spain, the Netherlands, Sweden, Switzerland, Belgium and the Nordic countries, with demand shaped by public hospital and university hospital ownership structures.

Asia-Pacific forms the fastest-growing regional concentration in this report, covered through China, Japan, South Korea, India, Australia, Singapore and Thailand, tied to oncology programme expansion and government tender activity across several emerging radiosurgery programmes.

Latin America and the Middle East and Africa together represent the smallest but fastest-emerging regional concentrations, covered through Brazil, Mexico, Argentina, Chile and Colombia, and Saudi Arabia, the UAE, South Africa, Egypt and Turkey respectively, with demand tied to capital equipment financing and public-private partnership procurement models.

Regional sizing, growth rates and country-level breakdowns are reserved for the full report rather than presented on this page.

REGIONAL OPPORTUNITY

Asia-Pacific's combination of government tender activity and a comparatively young installed base positions it as the region where new manufacturer entry and platform upgrade cycles are most likely to reshape competitive share over the next five years.

 

Leading Companies

Elekta, Accuray Incorporated, Varian Medical Systems (Siemens Healthineers), Brainlab, RaySearch Laboratories, ZAP Surgical Systems, ViewRay Technology Assets (Installed Base Assessment), Hitachi Healthcare, Shimadzu Corporation, Canon Medical Systems, GE HealthCare, Philips Healthcare, Mitsubishi Electric, IBA Dosimetry and Mevion Medical Systems are covered in the full report. An introduction to the supplier landscape by manufacturer type is available on the gamma knife equipment manufacturers page.

Beyond This Page

The full report extends well past the segmentation summarised here and into the commercial detail that shapes how Leksell Gamma Knife supply is actually won.

Buyer intelligence maps the buyer ecosystem across academic healthcare systems, cancer care networks, neuroscience institutes, government hospital groups and private hospital chains in full, including a dedicated strategic relevance assessment for Elekta.

Decision-maker mapping covers vendor selection criteria, contract value bands, sales cycle length and budget ownership across hospital administration, oncology programme leadership and government health authorities.

Competitive benchmarking compares manufacturers across installed base, procedure volumes, pricing positioning, service infrastructure and clinical evidence strength as named evaluation categories.

The market playbook covers installed base dynamics, technology adoption trends, reimbursement evolution and the regulatory landscape.

Pricing and procurement chapters cover capital equipment pricing analysis, service contract pricing analysis, total cost of ownership analysis and return on investment evaluation framework.

Go-to-market chapters set out hospital network targeting, government tender strategy, key opinion leader engagement strategy and major scientific congress activity.

Company profiles cover fifteen manufacturers across geographic footprint, product and service portfolio, certifications and regulatory approvals, and R&D and innovation initiatives.

Frequently Asked Questions

The market is estimated at approximately USD 475 Million in 2025 and is projected to reach approximately USD 620 Million by 2030, expanding at a compound annual growth rate of roughly 5.5 percent.

A capital equipment platform used in stereotactic radiosurgery. This report describes the category strictly as a market segment.

North America and Europe together account for the largest regional concentration, while Asia-Pacific forms the fastest-growing region tied to oncology programme expansion and government tender activity.

Oncology programme expansion and neurosurgery capacity growth is the leading driver, alongside technology modernisation among institutions operating earlier installed platforms.

The Icon is Elekta's current-generation platform, while earlier installed platforms remain in active clinical use across a large share of the more than 360-unit global installed base, a distinction that shapes which service, software and upgrade path a centre follows.

Brain metastases, acoustic neuroma, meningioma, arteriovenous malformations, trigeminal neuralgia, pituitary adenoma, gliomas, functional neurosurgery applications and other intracranial disorders are the nine treatment indication categories tracked in this report.

Academic medical centres, cancer hospitals and government healthcare institutions most commonly procure these systems, working through tender-based, direct purchase or strategic partnership procurement models.

FDA-regulated markets, CE-Mark markets and emerging regulatory jurisdictions together govern product approval and market entry sequencing.

Elekta manufactures the Leksell Gamma Knife platform itself, alongside a broader competitive landscape of diversified radiotherapy manufacturers and specialised radiosurgery technology providers covered in the full report.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Leksell Gamma Knife Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Oncology Programme Expansion and Neurosurgery Capacity Growth Across Hospital Systems Investing in Stereotactic Radiosurgery Capability.

3.3.2. Technology Modernisation and Replacement Demand Among Institutions Operating Earlier Installed Gamma Knife Platforms.

3.3.3. Clinical Differentiation Objectives Among Academic Medical Centres and Cancer Hospitals Building Out Neuro-Oncology Service Lines.

3.3.4. Growth in Government Tender and Public Healthcare Procurement Activity Supporting Capital Equipment Acquisition Across Public and Private Healthcare Systems.

3.3.5. Rising Software and Treatment Planning Investment Extending the Functional Life and Capability of the Existing Installed Base.

3.4. Restraints

3.4.1. High Capital Cost and Long Public-Sector and Academic-Institution Procurement Cycles Associated with a Single-Purpose Stereotactic Radiosurgery System.

3.4.2. Dependence on Government Tender and Public Healthcare Procurement Budgets, Which Are Outside Any Manufacturer's Control.

3.4.3. Competition from Alternative Radiosurgery and Radiotherapy Technologies for the Same Capital Equipment Budget.

3.4.4. Long Specification, Credentialing and Regulatory Approval Periods Before a New Manufacturer or Platform Gains Meaningful Installed Base Share.

3.5. Opportunities

3.5.1. Considerable Untapped Opportunity Identified in the Report Competitive Mapping.

3.5.2. Emerging Market Penetration Opportunities Across Latin America, Asia-Pacific and Middle East and Africa Markets Where Installed Base Remains Comparatively Limited.

3.5.3. Service Revenue Growth Opportunities Tied to Upgrades and Modernisation of the Existing Installed Base.

3.5.4. Growth in Software and Treatment Planning Capability, Which Several Manufacturers Are Using to Differentiate Their Platforms.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Product Type

4.1. Leksell Gamma Knife Icon

4.2. Earlier Installed Gamma Knife Platforms

4.3. Software and Treatment Planning Solutions

4.4. Service and Maintenance Programmes

4.5. Upgrades and Modernisation Services

5. Treatment Indication

5.1. Brain Metastases

5.2. Acoustic Neuroma

5.3. Meningioma

5.4. Arteriovenous Malformations (AVM)

5.5. Trigeminal Neuralgia

5.6. Pituitary Adenoma

5.7. Gliomas

5.8. Functional Neurosurgery Applications

5.9. Other Intracranial Disorders

6. Patient Volume Category

6.1. High-Volume Radiosurgery Centres

6.2. Mid-Volume Specialty Centres

6.3. Emerging Radiosurgery Programmes

7. End User

7.1. Academic Medical Centres

7.2. Cancer Hospitals

7.3. Neurosurgical Hospitals

7.4. Multi-Specialty Hospitals

7.5. Government Healthcare Institutions

7.6. Private Healthcare Groups

8. Ownership Model

8.1. Public Hospitals

8.2. Private Hospital Networks

8.3. University Hospitals

8.4. Research Institutions

9. Procurement Model

9.1. Direct Purchase

9.2. Tender-Based Procurement

9.3. Public Healthcare Procurement

9.4. Leasing and Financing Models

9.5. Strategic Partnership Models

10. Clinical Workflow

10.1. Standalone Radiosurgery Programmes

10.2. Integrated Oncology Centres

10.3. Multidisciplinary Brain Tumour Centres

11. Regulatory Environment

11.1. FDA-Regulated Markets

11.2. CE-Mark Markets

11.3. Emerging Regulatory Jurisdictions

12. Buyer Intelligence and Demand Landscape

12.1. Buyer Segmentation

12.1.1. Academic Healthcare Systems

12.1.2. Cancer Care Networks

12.1.3. Neuroscience Institutes

12.1.4. Government Hospital Groups

12.1.5. Private Hospital Chains

12.2. Buyer Industries

12.2.1. Neurosurgery

12.2.2. Radiation Oncology

12.2.3. Oncology Care Networks

12.2.4. Academic Research

12.2.5. Advanced Specialty Healthcare

12.3. Buyer Company Types

12.3.1. Public Healthcare Providers

12.3.2. Private Healthcare Operators

12.3.3. University Medical Centres

12.3.4. National Cancer Institutes

12.4. Country-Wise Buyer Mapping

12.4.1. United States

12.4.2. Brazil

12.4.3. Germany

12.4.4. China

12.4.5. Japan

12.4.6. India

12.4.7. United Kingdom

12.4.8. Saudi Arabia

12.5. Regional Demand Clusters

12.5.1. North America

12.5.2. Western Europe

12.5.3. East Asia

12.5.4. Latin America

12.5.5. Gulf Cooperation Council (GCC)

12.6. Buyer Scale Classification

12.6.1. National Referral Centres

12.6.2. Regional Specialty Centres

12.6.3. Local Advanced Treatment Facilities

12.7. Procurement Models

12.7.1. Government Tender

12.7.2. Direct Commercial Purchase

12.7.3. Public-Private Partnerships

12.7.4. Capital Equipment Financing

12.8. Buying Triggers

12.8.1. Oncology Programme Expansion

12.8.2. Neurosurgery Capacity Growth

12.8.3. Technology Modernisation

12.8.4. Clinical Differentiation

12.8.5. Reimbursement Opportunities

12.9. Decision-Maker Roles

12.9.1. Hospital CEO

12.9.2. Medical Director

12.9.3. Neurosurgery Director

12.9.4. Radiation Oncology Director

12.9.5. Procurement Committee

12.9.6. Finance Committee

12.10. Budget Ownership

12.10.1. Hospital Administration

12.10.2. Oncology Programme Leadership

12.10.3. Government Health Authorities

12.10.4. Healthcare Investment Boards

12.11. Vendor Selection Criteria

12.11.1. Clinical Outcomes

12.11.2. Installed Base Performance

12.11.3. Service Support

12.11.4. Treatment Throughput

12.11.5. Software Capabilities

12.11.6. Regulatory Compliance

12.12. Contract Value Bands

12.12.1. Initial System Acquisition

12.12.2. Service Agreements

12.12.3. Upgrade Contracts

12.12.4. Enterprise Oncology Investments

12.13. Sales Cycle Length

12.13.1. Public Sector Procurement

12.13.2. Private Hospital Procurement

12.13.3. Academic Institution Procurement

12.14. Strategic Relevance for Elekta

12.14.1. Strategic Relevance for Elekta

13. By Region

13.1. North America

13.2. Europe

13.3. Asia-Pacific

13.4. Latin America

13.5. Middle East and Africa

13.6. State and City Demand Clusters (Brazil, United States, Germany, China, India)

14. North America Leksell Gamma Knife Market - Global View with Spotlight on Latin America, North America, Europe, Asia-Pacific and Middle East/Africa Neurosurgical Radiosurgery Ecosystems Market Analysis and Forecast (2026–2030)

14.1. Introduction

14.2. Market Share Analysis

14.3. Market Size and Forecast

14.4. Market Size and Forecast, By Geography

14.4.1. United States

14.4.1.1. Market Share Analysis

14.4.1.2. Market Size and Forecast

14.4.1.3. By Product

14.4.1.4. By Technology

14.4.1.5. By Application

14.4.1.6. By Customer

14.4.2. Canada

14.4.2.1. Market Share Analysis

14.4.2.2. Market Size and Forecast

14.4.2.3. By Product

14.4.2.4. By Technology

14.4.2.5. By Application

14.4.2.6. By Customer

15. Europe Leksell Gamma Knife Market - Global View with Spotlight on Latin America, North America, Europe, Asia-Pacific and Middle East/Africa Neurosurgical Radiosurgery Ecosystems Market Analysis and Forecast (2026–2030)

15.1. Introduction

15.2. Market Share Analysis

15.3. Market Size and Forecast

15.4. Market Size and Forecast, By Geography

15.4.1. Germany

15.4.1.1. Market Share Analysis

15.4.1.2. Market Size and Forecast

15.4.1.3. By Product

15.4.1.4. By Technology

15.4.1.5. By Application

15.4.1.6. By Customer

15.4.2. United Kingdom

15.4.2.1. Market Share Analysis

15.4.2.2. Market Size and Forecast

15.4.2.3. By Product

15.4.2.4. By Technology

15.4.2.5. By Application

15.4.2.6. By Customer

15.4.3. France

15.4.3.1. Market Share Analysis

15.4.3.2. Market Size and Forecast

15.4.3.3. By Product

15.4.3.4. By Technology

15.4.3.5. By Application

15.4.3.6. By Customer

15.4.4. Italy

15.4.4.1. Market Share Analysis

15.4.4.2. Market Size and Forecast

15.4.4.3. By Product

15.4.4.4. By Technology

15.4.4.5. By Application

15.4.4.6. By Customer

15.4.5. Spain

15.4.5.1. Market Share Analysis

15.4.5.2. Market Size and Forecast

15.4.5.3. By Product

15.4.5.4. By Technology

15.4.5.5. By Application

15.4.5.6. By Customer

15.4.6. Netherlands

15.4.6.1. Market Share Analysis

15.4.6.2. Market Size and Forecast

15.4.6.3. By Product

15.4.6.4. By Technology

15.4.6.5. By Application

15.4.6.6. By Customer

15.4.7. Sweden

15.4.7.1. Market Share Analysis

15.4.7.2. Market Size and Forecast

15.4.7.3. By Product

15.4.7.4. By Technology

15.4.7.5. By Application

15.4.7.6. By Customer

15.4.8. Switzerland

15.4.8.1. Market Share Analysis

15.4.8.2. Market Size and Forecast

15.4.8.3. By Product

15.4.8.4. By Technology

15.4.8.5. By Application

15.4.8.6. By Customer

15.4.9. Belgium

15.4.9.1. Market Share Analysis

15.4.9.2. Market Size and Forecast

15.4.9.3. By Product

15.4.9.4. By Technology

15.4.9.5. By Application

15.4.9.6. By Customer

15.4.10. Nordic Countries

15.4.10.1. Market Share Analysis

15.4.10.2. Market Size and Forecast

15.4.10.3. By Product

15.4.10.4. By Technology

15.4.10.5. By Application

15.4.10.6. By Customer

16. Asia-Pacific Leksell Gamma Knife Market - Global View with Spotlight on Latin America, North America, Europe, Asia-Pacific and Middle East/Africa Neurosurgical Radiosurgery Ecosystems Market Analysis and Forecast (2026–2030)

16.1. Introduction

16.2. Market Share Analysis

16.3. Market Size and Forecast

16.4. Market Size and Forecast, By Geography

16.4.1. China

16.4.1.1. Market Share Analysis

16.4.1.2. Market Size and Forecast

16.4.1.3. By Product

16.4.1.4. By Technology

16.4.1.5. By Application

16.4.1.6. By Customer

16.4.2. Japan

16.4.2.1. Market Share Analysis

16.4.2.2. Market Size and Forecast

16.4.2.3. By Product

16.4.2.4. By Technology

16.4.2.5. By Application

16.4.2.6. By Customer

16.4.3. South Korea

16.4.3.1. Market Share Analysis

16.4.3.2. Market Size and Forecast

16.4.3.3. By Product

16.4.3.4. By Technology

16.4.3.5. By Application

16.4.3.6. By Customer

16.4.4. India

16.4.4.1. Market Share Analysis

16.4.4.2. Market Size and Forecast

16.4.4.3. By Product

16.4.4.4. By Technology

16.4.4.5. By Application

16.4.4.6. By Customer

16.4.5. Australia

16.4.5.1. Market Share Analysis

16.4.5.2. Market Size and Forecast

16.4.5.3. By Product

16.4.5.4. By Technology

16.4.5.5. By Application

16.4.5.6. By Customer

16.4.6. Singapore

16.4.6.1. Market Share Analysis

16.4.6.2. Market Size and Forecast

16.4.6.3. By Product

16.4.6.4. By Technology

16.4.6.5. By Application

16.4.6.6. By Customer

16.4.7. Thailand

16.4.7.1. Market Share Analysis

16.4.7.2. Market Size and Forecast

16.4.7.3. By Product

16.4.7.4. By Technology

16.4.7.5. By Application

16.4.7.6. By Customer

17. Latin America Leksell Gamma Knife Market - Global View with Spotlight on Latin America, North America, Europe, Asia-Pacific and Middle East/Africa Neurosurgical Radiosurgery Ecosystems Market Analysis and Forecast (2026–2030)

17.1. Introduction

17.2. Market Share Analysis

17.3. Market Size and Forecast

17.4. Market Size and Forecast, By Geography

17.4.1. Brazil

17.4.1.1. Market Share Analysis

17.4.1.2. Market Size and Forecast

17.4.1.3. By Product

17.4.1.4. By Technology

17.4.1.5. By Application

17.4.1.6. By Customer

17.4.2. Mexico

17.4.2.1. Market Share Analysis

17.4.2.2. Market Size and Forecast

17.4.2.3. By Product

17.4.2.4. By Technology

17.4.2.5. By Application

17.4.2.6. By Customer

17.4.3. Argentina

17.4.3.1. Market Share Analysis

17.4.3.2. Market Size and Forecast

17.4.3.3. By Product

17.4.3.4. By Technology

17.4.3.5. By Application

17.4.3.6. By Customer

17.4.4. Chile

17.4.4.1. Market Share Analysis

17.4.4.2. Market Size and Forecast

17.4.4.3. By Product

17.4.4.4. By Technology

17.4.4.5. By Application

17.4.4.6. By Customer

17.4.5. Colombia

17.4.5.1. Market Share Analysis

17.4.5.2. Market Size and Forecast

17.4.5.3. By Product

17.4.5.4. By Technology

17.4.5.5. By Application

17.4.5.6. By Customer

18. Middle East and Africa Leksell Gamma Knife Market - Global View with Spotlight on Latin America, North America, Europe, Asia-Pacific and Middle East/Africa Neurosurgical Radiosurgery Ecosystems Market Analysis and Forecast (2026–2030)

18.1. Introduction

18.2. Market Share Analysis

18.3. Market Size and Forecast

18.4. Market Size and Forecast, By Geography

18.4.1. Saudi Arabia

18.4.1.1. Market Share Analysis

18.4.1.2. Market Size and Forecast

18.4.1.3. By Product

18.4.1.4. By Technology

18.4.1.5. By Application

18.4.1.6. By Customer

18.4.2. UAE

18.4.2.1. Market Share Analysis

18.4.2.2. Market Size and Forecast

18.4.2.3. By Product

18.4.2.4. By Technology

18.4.2.5. By Application

18.4.2.6. By Customer

18.4.3. South Africa

18.4.3.1. Market Share Analysis

18.4.3.2. Market Size and Forecast

18.4.3.3. By Product

18.4.3.4. By Technology

18.4.3.5. By Application

18.4.3.6. By Customer

18.4.4. Egypt

18.4.4.1. Market Share Analysis

18.4.4.2. Market Size and Forecast

18.4.4.3. By Product

18.4.4.4. By Technology

18.4.4.5. By Application

18.4.4.6. By Customer

18.4.5. Turkey

18.4.5.1. Market Share Analysis

18.4.5.2. Market Size and Forecast

18.4.5.3. By Product

18.4.5.4. By Technology

18.4.5.5. By Application

18.4.5.6. By Customer

19. Competition Analysis

19.1. Market Positioning Overview

19.1.1. Global Market Structure

19.1.2. Premium Technology Positioning

19.1.3. Regional Competitive Dynamics

19.1.4. Installed Base Comparison

19.1.5. Value Proposition Assessment

19.2. Competitive Benchmarking Metrics

19.2.1. Estimated Market Position

19.2.2. Installed Base

19.2.3. Procedure Volumes

19.2.4. Pricing Positioning

19.2.5. Service Infrastructure

19.2.6. Clinical Evidence Strength

19.2.7. Global Coverage

19.2.8. Innovation Investments

19.2.9. Regulatory Approvals

19.3. Strategic Moves

19.3.1. Product Launches

19.3.2. Clinical Collaborations

19.3.3. Academic Partnerships

19.3.4. Service Network Expansion

19.3.5. Artificial Intelligence (AI) and Software Investments

19.3.6. Geographic Expansion Initiatives

19.4. Competitive Mapping & Gaps

19.4.1. Technology Positioning Matrix

19.4.2. Treatment Capability Mapping

19.4.3. Regional Coverage Gaps

19.4.4. Emerging Market Opportunities

19.4.5. Considerable Untapped Opportunity Assessment

19.4.6. Differentiation Opportunities for Elekta

20. Company Profiles

20.1. Elekta

20.1.1. Overview

20.1.2. Headquarters

20.1.3. Ownership Structure

20.1.4. Founding Year

20.1.5. Workforce Estimate

20.1.6. Geographic Footprint

20.1.7. Product and Service Portfolio

20.1.8. Target Customer Segments

20.1.9. Distribution and Go-to-Market (GTM) Strategy

20.1.10. Key Financials

20.1.11. Certifications and Regulatory Approvals

20.1.12. Partnerships and Alliances

20.1.13. R&D and Innovation Initiatives

20.1.14. Recent Developments

20.1.15. SWOT Snapshot

20.2. Accuray Incorporated

20.2.1. Overview

20.2.2. Headquarters

20.2.3. Ownership Structure

20.2.4. Founding Year

20.2.5. Workforce Estimate

20.2.6. Geographic Footprint

20.2.7. Product and Service Portfolio

20.2.8. Target Customer Segments

20.2.9. Distribution and Go-to-Market (GTM) Strategy

20.2.10. Key Financials

20.2.11. Certifications and Regulatory Approvals

20.2.12. Partnerships and Alliances

20.2.13. R&D and Innovation Initiatives

20.2.14. Recent Developments

20.2.15. SWOT Snapshot

20.3. Varian Medical Systems (Siemens Healthineers)

20.3.1. Overview

20.3.2. Headquarters

20.3.3. Ownership Structure

20.3.4. Founding Year

20.3.5. Workforce Estimate

20.3.6. Geographic Footprint

20.3.7. Product and Service Portfolio

20.3.8. Target Customer Segments

20.3.9. Distribution and Go-to-Market (GTM) Strategy

20.3.10. Key Financials

20.3.11. Certifications and Regulatory Approvals

20.3.12. Partnerships and Alliances

20.3.13. R&D and Innovation Initiatives

20.3.14. Recent Developments

20.3.15. SWOT Snapshot

20.4. Brainlab

20.4.1. Overview

20.4.2. Headquarters

20.4.3. Ownership Structure

20.4.4. Founding Year

20.4.5. Workforce Estimate

20.4.6. Geographic Footprint

20.4.7. Product and Service Portfolio

20.4.8. Target Customer Segments

20.4.9. Distribution and Go-to-Market (GTM) Strategy

20.4.10. Key Financials

20.4.11. Certifications and Regulatory Approvals

20.4.12. Partnerships and Alliances

20.4.13. R&D and Innovation Initiatives

20.4.14. Recent Developments

20.4.15. SWOT Snapshot

20.5. RaySearch Laboratories

20.5.1. Overview

20.5.2. Headquarters

20.5.3. Ownership Structure

20.5.4. Founding Year

20.5.5. Workforce Estimate

20.5.6. Geographic Footprint

20.5.7. Product and Service Portfolio

20.5.8. Target Customer Segments

20.5.9. Distribution and Go-to-Market (GTM) Strategy

20.5.10. Key Financials

20.5.11. Certifications and Regulatory Approvals

20.5.12. Partnerships and Alliances

20.5.13. R&D and Innovation Initiatives

20.5.14. Recent Developments

20.5.15. SWOT Snapshot

20.6. ZAP Surgical Systems

20.6.1. Overview

20.6.2. Headquarters

20.6.3. Ownership Structure

20.6.4. Founding Year

20.6.5. Workforce Estimate

20.6.6. Geographic Footprint

20.6.7. Product and Service Portfolio

20.6.8. Target Customer Segments

20.6.9. Distribution and Go-to-Market (GTM) Strategy

20.6.10. Key Financials

20.6.11. Certifications and Regulatory Approvals

20.6.12. Partnerships and Alliances

20.6.13. R&D and Innovation Initiatives

20.6.14. Recent Developments

20.6.15. SWOT Snapshot

20.7. ViewRay Technology Assets (Installed Base Assessment)

20.7.1. Overview

20.7.2. Headquarters

20.7.3. Ownership Structure

20.7.4. Founding Year

20.7.5. Workforce Estimate

20.7.6. Geographic Footprint

20.7.7. Product and Service Portfolio

20.7.8. Target Customer Segments

20.7.9. Distribution and Go-to-Market (GTM) Strategy

20.7.10. Key Financials

20.7.11. Certifications and Regulatory Approvals

20.7.12. Partnerships and Alliances

20.7.13. R&D and Innovation Initiatives

20.7.14. Recent Developments

20.7.15. SWOT Snapshot

20.8. Hitachi Healthcare

20.8.1. Overview

20.8.2. Headquarters

20.8.3. Ownership Structure

20.8.4. Founding Year

20.8.5. Workforce Estimate

20.8.6. Geographic Footprint

20.8.7. Product and Service Portfolio

20.8.8. Target Customer Segments

20.8.9. Distribution and Go-to-Market (GTM) Strategy

20.8.10. Key Financials

20.8.11. Certifications and Regulatory Approvals

20.8.12. Partnerships and Alliances

20.8.13. R&D and Innovation Initiatives

20.8.14. Recent Developments

20.8.15. SWOT Snapshot

20.9. Shimadzu Corporation

20.9.1. Overview

20.9.2. Headquarters

20.9.3. Ownership Structure

20.9.4. Founding Year

20.9.5. Workforce Estimate

20.9.6. Geographic Footprint

20.9.7. Product and Service Portfolio

20.9.8. Target Customer Segments

20.9.9. Distribution and Go-to-Market (GTM) Strategy

20.9.10. Key Financials

20.9.11. Certifications and Regulatory Approvals

20.9.12. Partnerships and Alliances

20.9.13. R&D and Innovation Initiatives

20.9.14. Recent Developments

20.9.15. SWOT Snapshot

20.10. Canon Medical Systems

20.10.1. Overview

20.10.2. Headquarters

20.10.3. Ownership Structure

20.10.4. Founding Year

20.10.5. Workforce Estimate

20.10.6. Geographic Footprint

20.10.7. Product and Service Portfolio

20.10.8. Target Customer Segments

20.10.9. Distribution and Go-to-Market (GTM) Strategy

20.10.10. Key Financials

20.10.11. Certifications and Regulatory Approvals

20.10.12. Partnerships and Alliances

20.10.13. R&D and Innovation Initiatives

20.10.14. Recent Developments

20.10.15. SWOT Snapshot

20.11. GE HealthCare

20.11.1. Overview

20.11.2. Headquarters

20.11.3. Ownership Structure

20.11.4. Founding Year

20.11.5. Workforce Estimate

20.11.6. Geographic Footprint

20.11.7. Product and Service Portfolio

20.11.8. Target Customer Segments

20.11.9. Distribution and Go-to-Market (GTM) Strategy

20.11.10. Key Financials

20.11.11. Certifications and Regulatory Approvals

20.11.12. Partnerships and Alliances

20.11.13. R&D and Innovation Initiatives

20.11.14. Recent Developments

20.11.15. SWOT Snapshot

20.12. Philips Healthcare

20.12.1. Overview

20.12.2. Headquarters

20.12.3. Ownership Structure

20.12.4. Founding Year

20.12.5. Workforce Estimate

20.12.6. Geographic Footprint

20.12.7. Product and Service Portfolio

20.12.8. Target Customer Segments

20.12.9. Distribution and Go-to-Market (GTM) Strategy

20.12.10. Key Financials

20.12.11. Certifications and Regulatory Approvals

20.12.12. Partnerships and Alliances

20.12.13. R&D and Innovation Initiatives

20.12.14. Recent Developments

20.12.15. SWOT Snapshot

20.13. Mitsubishi Electric

20.13.1. Overview

20.13.2. Headquarters

20.13.3. Ownership Structure

20.13.4. Founding Year

20.13.5. Workforce Estimate

20.13.6. Geographic Footprint

20.13.7. Product and Service Portfolio

20.13.8. Target Customer Segments

20.13.9. Distribution and Go-to-Market (GTM) Strategy

20.13.10. Key Financials

20.13.11. Certifications and Regulatory Approvals

20.13.12. Partnerships and Alliances

20.13.13. R&D and Innovation Initiatives

20.13.14. Recent Developments

20.13.15. SWOT Snapshot

20.14. IBA Dosimetry

20.14.1. Overview

20.14.2. Headquarters

20.14.3. Ownership Structure

20.14.4. Founding Year

20.14.5. Workforce Estimate

20.14.6. Geographic Footprint

20.14.7. Product and Service Portfolio

20.14.8. Target Customer Segments

20.14.9. Distribution and Go-to-Market (GTM) Strategy

20.14.10. Key Financials

20.14.11. Certifications and Regulatory Approvals

20.14.12. Partnerships and Alliances

20.14.13. R&D and Innovation Initiatives

20.14.14. Recent Developments

20.14.15. SWOT Snapshot

20.15. Mevion Medical Systems

20.15.1. Overview

20.15.2. Headquarters

20.15.3. Ownership Structure

20.15.4. Founding Year

20.15.5. Workforce Estimate

20.15.6. Geographic Footprint

20.15.7. Product and Service Portfolio

20.15.8. Target Customer Segments

20.15.9. Distribution and Go-to-Market (GTM) Strategy

20.15.10. Key Financials

20.15.11. Certifications and Regulatory Approvals

20.15.12. Partnerships and Alliances

20.15.13. R&D and Innovation Initiatives

20.15.14. Recent Developments

20.15.15. SWOT Snapshot

Frequently Asked Questions

The market is estimated at approximately USD 475 Million in 2025 and is projected to reach approximately USD 620 Million by 2030, expanding at a compound annual growth rate of roughly 5.5 percent.

A capital equipment platform used in stereotactic radiosurgery. This report describes the category strictly as a market segment.

North America and Europe together account for the largest regional concentration, while Asia-Pacific forms the fastest-growing region tied to oncology programme expansion and government tender activity.

Oncology programme expansion and neurosurgery capacity growth is the leading driver, alongside technology modernisation among institutions operating earlier installed platforms.

The Icon is Elekta's current-generation platform, while earlier installed platforms remain in active clinical use across a large share of the more than 360-unit global installed base, a distinction that shapes which service, software and upgrade path a centre follows.

Brain metastases, acoustic neuroma, meningioma, arteriovenous malformations, trigeminal neuralgia, pituitary adenoma, gliomas, functional neurosurgery applications and other intracranial disorders are the nine treatment indication categories tracked in this report.

Academic medical centres, cancer hospitals and government healthcare institutions most commonly procure these systems, working through tender-based, direct purchase or strategic partnership procurement models.

FDA-regulated markets, CE-Mark markets and emerging regulatory jurisdictions together govern product approval and market entry sequencing.

Elekta manufactures the Leksell Gamma Knife platform itself, alongside a broader competitive landscape of diversified radiotherapy manufacturers and specialised radiosurgery technology providers covered in the full report.

Inquire Before Buying Request Free Sample Ask For Discount

Leksell Gamma Knife market separated from the broader stereotactic radiosurgery and surgery devices categories

Gamma Knife systems are frequently reported inside much larger stereotactic radiosurgery or stereotactic surgery devices categories, which span linear accelerator-based radiosurgery platforms, image-guided neurosurgical navigation systems and stereotactic biopsy devices not comparable with the activity described here. Several published categories place the broader stereotactic radiosurgery and surgery devices markets in the tens of billions of dollars, a scope far wider than the Gamma Knife-specific platform, software, service and upgrade activity this estimate covers. This estimate covers Leksell Gamma Knife systems and directly related software, service, maintenance, upgrade and modernisation offerings only. The snapshot table states that boundary so the figure is not mistaken for anything larger.

Triangulation from published Gamma Knife-specific market estimates

Several independent published sources track the Gamma Knife category specifically rather than the broader stereotactic radiosurgery category: one places the global Gamma Knife market at approximately USD 504.8 Million in 2026 growing to approximately USD 626.4 Million by 2030 at a 5.0 percent CAGR, implying a 2025 base of approximately USD 481 Million, and a second places it at approximately USD 493.2 Million in 2026 growing to approximately USD 727.0 Million by 2033 at a 5.7 percent CAGR, implying a 2025 base of approximately USD 467 Million. Averaging these two independently derived 2025 bases produces an approximately USD 474 Million starting point, and USD 475 Million was adopted.

Installed-base cross-check

Elekta has publicly described more than 360 Leksell Gamma Knife systems installed and in clinical use worldwide, with cumulative patients treated surpassing one million. Applying an estimated blended annual revenue per installed system, combining service and maintenance contracts, software and treatment planning licensing, periodic upgrades and modernisation work, and an amortised share of new platform sales, across this installed base produces a comparable annual market range, supporting the approximately USD 475 Million 2025 estimate rather than the far larger figures reported for the broader stereotactic radiosurgery and surgery devices categories.

Forecast basis and its principal sensitivity

The forecast to 2030 assumes government tender and public healthcare procurement budgets, and academic and private hospital capital equipment investment, continue broadly on recent trends, applying a blended 5.5 percent CAGR toward the upper end of the two triangulated Gamma Knife-specific growth rates given this market's documented emerging-market penetration and installed-base modernisation activity. The pace at which the more than 360-unit global installed base reaches its next upgrade or replacement cycle, and the pace of new installations across Asia-Pacific, Latin America and Middle East and Africa markets, are the material sensitivities.

Frequently Asked Questions

The market is estimated at approximately USD 475 Million in 2025 and is projected to reach approximately USD 620 Million by 2030, expanding at a compound annual growth rate of roughly 5.5 percent.

A capital equipment platform used in stereotactic radiosurgery. This report describes the category strictly as a market segment.

North America and Europe together account for the largest regional concentration, while Asia-Pacific forms the fastest-growing region tied to oncology programme expansion and government tender activity.

Oncology programme expansion and neurosurgery capacity growth is the leading driver, alongside technology modernisation among institutions operating earlier installed platforms.

The Icon is Elekta's current-generation platform, while earlier installed platforms remain in active clinical use across a large share of the more than 360-unit global installed base, a distinction that shapes which service, software and upgrade path a centre follows.

Brain metastases, acoustic neuroma, meningioma, arteriovenous malformations, trigeminal neuralgia, pituitary adenoma, gliomas, functional neurosurgery applications and other intracranial disorders are the nine treatment indication categories tracked in this report.

Academic medical centres, cancer hospitals and government healthcare institutions most commonly procure these systems, working through tender-based, direct purchase or strategic partnership procurement models.

FDA-regulated markets, CE-Mark markets and emerging regulatory jurisdictions together govern product approval and market entry sequencing.

Elekta manufactures the Leksell Gamma Knife platform itself, alongside a broader competitive landscape of diversified radiotherapy manufacturers and specialised radiosurgery technology providers covered in the full report.

Inquire Before Buying Request Free Sample Ask For Discount